Immunic (IMUX) 2024 Cantor Fitzgerald Global Healthcare Conference summary

Program and pipeline overview

• Developing oral therapies for chronic autoimmune and inflammatory diseases, with two clinical-stage and one preclinical program.

• Lead asset vidofludimus calcium is in phase 3 for relapsing MS and advanced phase 2 for progressive MS, also showing activity in ulcerative colitis.

• IMU-856, a SIRT6 modulator, has shown clinical proof of concept in celiac disease.

ECTRIMS conference highlights

• Four presentations accepted, covering unmet needs in MS, neuroprotection, and progression independent of relapse activity (PIRA).

• Presented biomarker data from the CALIPER study and mechanistic data on immune response.

• Highlighted first-in-class neuroprotection via Nurr1 activation.

Mechanism of action and clinical validation

• Vidofludimus calcium acts as both a DHODH inhibitor and potent Nurr1 activator, targeting neuroprotection.

• Nurr1 upregulation is associated with protective effects in MS, especially during pregnancy.

• Dual mechanism aims to address both relapse-associated and progression independent disability worsening.